{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-002605","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2026-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.966763+00:00","generated_at":"2026-05-16T05:38:33.060832+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eton Pharmaceuticals licenses U.S. rights to ultra-rare disease candidate; FDA under review","bullets":["Licensed product is first/only generic alternative for condition affecting <100 U.S. patients.","Product currently under FDA review; expected approval and launch mid-2026.","Deal aligns with Eton's commercial infrastructure; adds to pipeline of ultra-rare disease products.","CEO cites opportunity to bring improved patient experience via Eton Cares program.","Eton has eight commercial rare disease products and five late-stage candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-002605","json":"https://secwatch.observer/filing/0001437749-26-002605.json","markdown":"https://secwatch.observer/filing/0001437749-26-002605.md","text":"https://secwatch.observer/filing/0001437749-26-002605.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926002605/0001437749-26-002605-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926002605/eton20260130_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:38:33.060832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}